Literature DB >> 1639854

Targeted disruption of the tissue inhibitor of metalloproteinases gene increases the invasive behavior of primitive mesenchymal cells derived from embryonic stem cells in vitro.

C M Alexander1, Z Werb.   

Abstract

The metalloproteinase family of proteolytic enzymes can degrade extracellular matrix and facilitate invasive migration. This class of enzymes is specifically inhibited by the tissue inhibitor of metalloproteinases (TIMP-1). Using homologous recombination, we have disrupted the gene encoding TIMP-1 in pluripotent embryonic stem cells. Because the TIMP-1 gene is X linked and is hemizygous in embryonic stem cells, we have been able to study the effect of this mutation in culture. Using a basement membrane invasion assay, we found that the mutant cells, differentiated in low concentrations of serum with retinoic acid, were more invasive than their normal cell counterparts, and that this was specifically reversed by adding exogenous TIMP-1 protein. The invasive cell population had characteristics of an early population of primitive mesenchymal cells, including expression of vimentin and a transient period of invasiveness from 4-8 d after initiation of differentiation. Therefore, metalloproteinase activity can be rate limiting for cell invasion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1639854      PMCID: PMC2289547          DOI: 10.1083/jcb.118.3.727

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  40 in total

Review 1.  Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.

Authors:  L A Liotta; P S Steeg; W G Stetler-Stevenson
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

2.  Tumor cell invasion inhibited by TIMP-2.

Authors:  A Albini; A Melchiori; L Santi; L A Liotta; P D Brown; W G Stetler-Stevenson
Journal:  J Natl Cancer Inst       Date:  1991-06-05       Impact factor: 13.506

3.  Secretion of a putative metalloproteinase inhibitor by ovine granulosa cells and luteal tissue.

Authors:  M F Smith; R M Moor
Journal:  J Reprod Fertil       Date:  1991-03

Review 4.  Matrix metalloproteinases and their inhibitors in connective tissue remodeling.

Authors:  J F Woessner
Journal:  FASEB J       Date:  1991-05       Impact factor: 5.191

5.  Formation of cytoskeletal elements during mouse embryogenesis. II. Epithelial differentiation and intermediate-sized filaments in early postimplantation embryos.

Authors:  B W Jackson; C Grund; S Winter; W W Franke; K Illmensee
Journal:  Differentiation       Date:  1981       Impact factor: 3.880

6.  Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor.

Authors:  Y A DeClerck; T D Yean; D Chan; H Shimada; K E Langley
Journal:  Cancer Res       Date:  1991-04-15       Impact factor: 12.701

7.  Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72-kDa gelatinase. Identification of a stabilization site.

Authors:  E W Howard; M J Banda
Journal:  J Biol Chem       Date:  1991-09-25       Impact factor: 5.157

8.  Control of mammary epithelial differentiation: basement membrane induces tissue-specific gene expression in the absence of cell-cell interaction and morphological polarity.

Authors:  C H Streuli; N Bailey; M J Bissell
Journal:  J Cell Biol       Date:  1991-12       Impact factor: 10.539

9.  92-kD type IV collagenase mediates invasion of human cytotrophoblasts.

Authors:  C L Librach; Z Werb; M L Fitzgerald; K Chiu; N M Corwin; R A Esteves; D Grobelny; R Galardy; C H Damsky; S J Fisher
Journal:  J Cell Biol       Date:  1991-04       Impact factor: 10.539

10.  Metalloproteinases mediate extracellular matrix degradation by cells from mouse blastocyst outgrowths.

Authors:  O Behrendtsen; C M Alexander; Z Werb
Journal:  Development       Date:  1992-02       Impact factor: 6.868

View more
  26 in total

1.  Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis.

Authors:  L Guedez; A J McMarlin; D W Kingma; T A Bennett; M Stetler-Stevenson; W G Stetler-Stevenson
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.

Authors:  L Yan; M A Moses
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 3.  Demystified ... gene knockouts.

Authors:  J P Iredale
Journal:  Mol Pathol       Date:  1999-06

4.  Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue.

Authors:  Irene Vejgaard Sorensen; Claus Fenger; Henrik Winther; Niels T Foged; Ulrik Lademann; Nils Brünner; Pernille A Usher
Journal:  J Histochem Cytochem       Date:  2006-03-03       Impact factor: 2.479

Review 5.  The role of tissue inhibitor of metalloproteinase-1 in specific aspects of cancer progression and reproduction.

Authors:  R Khokha; P Waterhouse
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells.

Authors:  R D Kenagy; S T Nikkari; H G Welgus; A W Clowes
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 7.  Matrix degrading metalloproteinases.

Authors:  B W Ennis; L M Matrisian
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 8.  Utilization of transgenic mice in the study of matrix degrading proteinases and their inhibitors.

Authors:  R Khokha; D C Martin; J E Fata
Journal:  Cancer Metastasis Rev       Date:  1995-06       Impact factor: 9.264

Review 9.  A glimpse of matrix metalloproteinases in diabetic nephropathy.

Authors:  X Xu; L Xiao; P Xiao; S Yang; G Chen; F Liu; Y S Kanwar; L Sun
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

Review 10.  Type IV collagenases in invasive tumors.

Authors:  K Tryggvason; M Höyhtyä; C Pyke
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.